Patents by Inventor Paul D. Ponath

Paul D. Ponath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of identifying inhibitors of C—C chemokine receptor 3
    Patent number: 6994977
    Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: February 7, 2006
    Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham & Women's Hospital
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Methods of inhibiting GPR-9-6 function
    Patent number: 6936248
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: August 30, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brain A. Zabel, Paul D. Ponath
  • Methods of identifying agents which inhibit GPR-9-6
    Patent number: 6884574
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: April 26, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • G protein-coupled receptor gene and methods of use therefor
    Patent number: 6806061
    Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C-C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof, and to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: October 19, 2004
    Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
    Publication number: 20040033561
    Abstract: Featured are DNA molecules, expression vectors, and host cells useful for creation of immunoglobulins, as well as novel immunoglobulin molecules termed monobodies. Additionally provided are methods of production of immunoglobulins, including monobodies, as well as methods of using the disclosed immunoglobulin and monobody constructs, expression vectors and host cells containing DNA encoding molecules for production of immunoglobulin and monobody proteins.
    Type: Application
    Filed: October 17, 2002
    Publication date: February 19, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Theresa L. O'Keefe, Judith Jacques Healey, Walter Newman, Paul D. Ponath, Bruce A. Keyt
  • Methods of identifying agents which bind GPR-9-6
    Patent number: 6689570
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: February 10, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Method of identifying inhibitors of C-C chemokine receptor 3
    Publication number: 20030143684
    Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C-C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.
    Type: Application
    Filed: October 28, 2002
    Publication date: July 31, 2003
    Applicants: Children's Medical Center Corporation, Brigham & Women's Hospital, Millennium Pharmaceuticals, Inc.
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Method of identifying inhibitors of C—C chemokine receptor 3
    Patent number: 6537764
    Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: March 25, 2003
    Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham & Women's Hospital
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Methods of identifying agents which inhibit GPR-9-6
    Publication number: 20030022238
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 28, 2001
    Publication date: January 30, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Methods of treating inflammatory disease using antibodies which bind GPR-9-6
    Publication number: 20020141991
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: October 23, 2001
    Publication date: October 3, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Methods of identifying agents which bind GPR-9-6
    Publication number: 20020119504
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 13, 2001
    Publication date: August 29, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
    Patent number: 6329159
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: December 11, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath